Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $19000.0.

  • Inhibrx Biosciences' Gains from Investment Securities rose 15757.58% to $19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $116000.0, marking a year-over-year decrease of 9776.28%. This contributed to the annual value of $3.7 million for FY2024, which is 12441.86% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Gains from Investment Securities of $19000.0 as of Q3 2025, which was up 15757.58% from $6000.0 recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Gains from Investment Securities registered a high of $2.2 million during Q2 2024, and its lowest value of -$33000.0 during Q3 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was $19000.0 (2025), whereas its average is $588888.9.
  • As far as peak fluctuations go, Inhibrx Biosciences' Gains from Investment Securities tumbled by 320000.0% in 2024, and later soared by 15757.58% in 2025.
  • Inhibrx Biosciences' Gains from Investment Securities (Quarter) stood at $1.6 million in 2023, then plummeted by 92.73% to $119000.0 in 2024, then tumbled by 84.03% to $19000.0 in 2025.
  • Its last three reported values are $19000.0 in Q3 2025, $6000.0 for Q2 2025, and -$28000.0 during Q1 2025.